Diligence memo · auto-generated · as of July 3, 2026
CHARM Therapeutics Inc.
CHARM Therapeutics Inc. looks fair against its niche peers and is active on financing cadence.
Businessfiled
CHARM Therapeutics Inc. operates in Pharma, based in LONDON.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
CHARM Therapeutics Inc. has raised $87M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $37M on 2022-04-18.
Most recent recorded round closed around 2025-08-19.
Valuation (modeled)modeled
Provath models CHARM Therapeutics Inc. at approximately $77M (range $36M–$111M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.80× the median modeled value of Series B Pharma companies in 2025–2027 (8 peers) — value vs value, same stage and era. Within the normal band (80% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 15 months.
Last raise 10 mo ago; this sector typically re-raises about every 16 months.
Raising on or ahead of the sector's normal rhythm.
The last round was 1.2× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 90% of Pharma peers (310 compared).
Modeled value ranks above 62% of those peers.
Closest niche peers: Juvena Therapeutics, Inc., Alessa Therapeutics, Inc., Amani Therapeutics, Inc., Shenandoah Therapeutics Inc., Atlas Oncology Holdings Inc..
Peoplefiled
12 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.